{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:25:29Z","timestamp":1769192729702,"version":"3.49.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jbo.2024.100596","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T23:44:21Z","timestamp":1710978261000},"page":"100596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-5066","authenticated-orcid":false,"given":"Gennady N.","family":"Machak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8yvind S.","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara N.","family":"Romanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey V.","family":"Kovalev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jbo.2024.100596_b0005","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2024.100596_b0010","unstructured":"Flanagan AM Larousserie F O'Donnell PG Yoshida A. Giant cell tumour of bone. In: Soft Tissue and Bone Tumours. WHO Classification of Tumours, 5th Edition, Volume 3 2020: 440-446. ISBN13 978-92-832-4502-5."},{"key":"10.1016\/j.jbo.2024.100596_b0015","doi-asserted-by":"crossref","unstructured":"Forsyth RG, Kren\u00e1cs T, Athanasou N, Hogendoorn PCW. Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m\/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis. Cancers (Basel). Oct 13;13(20):5119. doi: 10.3390\/cancers13205119.","DOI":"10.3390\/cancers13205119"},{"key":"10.1016\/j.jbo.2024.100596_b0020","doi-asserted-by":"crossref","unstructured":"Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013 Dec;45(12):1479-82. doi: 10.1038\/ng.2814. Epub 2013 Oct 27. Erratum in: Nat Genet. 2014 Mar;46(3):316. Goodie, Victoria [corrected to Goody, Victoria].","DOI":"10.1038\/ng0314-316"},{"issue":"12","key":"10.1016\/j.jbo.2024.100596_b0025","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41418-022-01031-x","article-title":"Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone","volume":"29","author":"Cottone","year":"2022","journal-title":"Cell Death Differ."},{"issue":"448","key":"10.1016\/j.jbo.2024.100596_b0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2019.02.001","article-title":"Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells","volume":"28","author":"Fellenberg","year":"2019","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.jbo.2024.100596_b0035","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/2159-8290.CD-20-0461","article-title":"H3.3 G34W promotes growth and impedes differentiation of osteoblast-like mesenchymal progenitors in Giant cell tumor of bone","volume":"10","author":"Khazaei","year":"2020","journal-title":"Cancer Discov."},{"issue":"489","key":"10.1016\/j.jbo.2024.100596_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.05.031","article-title":"The two faces of giant cell tumor of bone","volume":"1","author":"Scotto di Carlo","year":"2020","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.jbo.2024.100596_b0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1359\/jbmr.2002.17.2.257","article-title":"Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor","volume":"17","author":"Kubota","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.jbo.2024.100596_b0050","first-page":"2219","article-title":"Expression of bone morphogenetic proteins in giant cell tumor of bone","volume":"29","author":"Kudo","year":"2009","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.jbo.2024.100596_b0055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semcdb.2008.07.016","article-title":"Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption","volume":"19","author":"Sims","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bone.2012.10.002","article-title":"Giant cell tumor of bone: a basic science perspective","volume":"52","author":"Cowan","year":"2013","journal-title":"Bone"},{"issue":"15","key":"10.1016\/j.jbo.2024.100596_b0065","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/cancers13153647","article-title":"Current concepts in the treatment of Giant cell tumors of bone","volume":"13","author":"Tsukamoto","year":"2021","journal-title":"Cancers (basel)."},{"issue":"6","key":"10.1016\/j.jbo.2024.100596_b0070","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1053\/j.jfas.2014.08.016","article-title":"Giant cell tumors of the foot and ankle bones: high recurrence rates after surgical treatment","volume":"54","author":"Rajani","year":"2015","journal-title":"J. Foot Ankle Surg."},{"key":"10.1016\/j.jbo.2024.100596_b0075","doi-asserted-by":"crossref","unstructured":"Veng C, J\u00f8rgensen PH, Krog-Mikkelsen I, Stilling M. Measurement of bone mineral density as an efficacy marker in denosumab treatment of giant cell tumour of bone. BMJ Case Rep. 2017 Oct 23;2017:bcr2017220369. doi: 10.1136\/bcr-2017-220369.","DOI":"10.1136\/bcr-2017-220369"},{"issue":"14","key":"10.1016\/j.jbo.2024.100596_b0080","article-title":"Surgical options and reconstruction strategies for primary bone tumors of distal tibia: a systematic review of complications and functional outcome","volume":"4","author":"Zhao","year":"2018","journal-title":"J Bone Oncol."},{"key":"10.1016\/j.jbo.2024.100596_b0085","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Bone Cancer Version 1.2024 \u2014 August 7, 2023 https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1418."},{"issue":"10","key":"10.1016\/j.jbo.2024.100596_b0090","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2407-10-462","article-title":"Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant cell tumour of bone","volume":"29","author":"Balke","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2024.100596_b0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.blo.0000141372.54456.80","article-title":"Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis","volume":"426","author":"Chang","year":"2004","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"6","key":"10.1016\/j.jbo.2024.100596_b0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/01913120390248629","article-title":"Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration","volume":"27","author":"Cheng","year":"2003","journal-title":"Ultrastruct. Pathol."},{"issue":"6","key":"10.1016\/j.jbo.2024.100596_b0105","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jcot.2019.09.011","article-title":"Role of intravenous zoledronic acid in management of giant cell tumor of bone- a prospective, randomized, clinical, radiological and electron microscopic analysis","volume":"10","author":"Dubey","year":"2019","journal-title":"J Clin Orthop Trauma."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12253-017-0362-8","article-title":"In vitro study of the effects of denosumab on Giant cell tumor of bone: Comparison with zoledronic acid","volume":"25","author":"Shibuya","year":"2019","journal-title":"Pathol. Oncol. Res."},{"issue":"9","key":"10.1016\/j.jbo.2024.100596_b0115","article-title":"Combination of melatonin and zoledronic acid suppressed the Giant cell tumor of bone in vitro and in vivo","volume":"10","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.jbo.2024.100596_b0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/0284185121989515","article-title":"Utility of intraoperative magnetic resonance imaging for giant cell tumor of bone after denosumab treatment: a pilot study","volume":"63","author":"Furuta","year":"2022","journal-title":"Acta Radiol."},{"issue":"3","key":"10.1016\/j.jbo.2024.100596_b0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jor.21249","article-title":"Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG\/RANKL mRNA expression in stromal cells of giant cell tumor of bone","volume":"29","author":"Lau","year":"2011","journal-title":"J. Orthop. Res."},{"issue":"6","key":"10.1016\/j.jbo.2024.100596_b0130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/03008207.2013.848202","article-title":"Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone","volume":"54","author":"Lau","year":"2013","journal-title":"Connect. Tissue Res."},{"issue":"6","key":"10.1016\/j.jbo.2024.100596_b0135","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/03008207.2015.1075519","article-title":"A mouse model of luciferasetransfected stromal cells of giant cell tumor of bone","volume":"56","author":"Lau","year":"2015","journal-title":"Connect. Tissue Res."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0140","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2106\/JBJS.H.01679","article-title":"Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines","volume":"92","author":"Zwolak","year":"2010","journal-title":"J. Bone Joint Surg. Am."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00223-004-0120-2","article-title":"Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone","volume":"75","author":"Cheng","year":"2004","journal-title":"Calcif. Tissue Int."},{"issue":"9","key":"10.1016\/j.jbo.2024.100596_b0150","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.7314\/APJCP.2013.14.9.5379","article-title":"Stimulation of osteogenic differentiation in stromal cells of giant cell tumour of bone by zoledronic acid","volume":"14","author":"Yang","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"29","key":"10.1016\/j.jbo.2024.100596_b0155","doi-asserted-by":"crossref","first-page":"11240","DOI":"10.1074\/jbc.RA119.007625","article-title":"Mature osteoclast-derived apoptotic bodies promote osteogenic differentiation via RANKL-mediated reverse signaling","volume":"294","author":"Ma","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jbo.2024.100596_b0160","first-page":"225","article-title":"Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis","volume":"37","author":"Stepan","year":"2003","journal-title":"Endocr. Regul."},{"key":"10.1016\/j.jbo.2024.100596_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116353","article-title":"RANKL biology","volume":"159","author":"Takegahara","year":"2022","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.jbo.2024.100596_b0170","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bone.2007.12.225","article-title":"Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells","volume":"42","author":"Coxon","year":"2008","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.jbo.2024.100596_b0175","article-title":"Role of zoledronic acid supplementation in reducing post-surgical recurrence of Giant cell tumor of bone: a meta-analysis of Comparative studies","volume":"13","author":"Kumar","year":"2021","journal-title":"Cureus."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/ortho.IJOrtho_216_17","article-title":"Effect of intravenous zoledronic acid on histopathology and recurrence after extended curettage in Giant cell tumors of bone: a Comparative prospective study","volume":"52","author":"Kundu","year":"2018","journal-title":"Indian J Orthop."},{"issue":"10","key":"10.1016\/j.jbo.2024.100596_b0185","article-title":"Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone","volume":"5","author":"Luo","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0190","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bone.2007.08.038","article-title":"Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study","volume":"42","author":"Tse","year":"2008","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.jbo.2024.100596_b0195","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00402-019-03167-x","article-title":"Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature","volume":"139","author":"Luengo-Alonso","year":"2019","journal-title":"Arch. Orthop. Trauma Surg."},{"issue":"11","key":"10.1016\/j.jbo.2024.100596_b0200","article-title":"Single-cell RNA sequencing reveals the migration of osteoclasts in Giant cell tumor of bone","volume":"24","author":"Feng","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2024.100596_b0205","doi-asserted-by":"crossref","first-page":"749","DOI":"10.21873\/anticanres.11373","article-title":"Pathogenesis of osteosclerotic change following treatment with an antibody against RANKL for Giant cell tumour of the bone","volume":"37","author":"Rosario","year":"2017","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.jbo.2024.100596_b0210","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1245\/s10434-015-4634-9","article-title":"Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone","volume":"22","author":"Rutkowski","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"35","key":"10.1016\/j.jbo.2024.100596_b0215","article-title":"Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: a randomized clinical trial","volume":"24","author":"Yue","year":"2022","journal-title":"J Bone Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0220","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jos.2020.11.005","article-title":"Clinical and pathological analysis of giant cell tumor of bone with denosumab treatment and local recurrence","volume":"27","author":"Hayashida","year":"2022","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.jbo.2024.100596_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2021.151882","article-title":"Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): analysis of 21 cases","volume":"57","author":"Yang","year":"2022","journal-title":"Ann. Diagn. Pathol."},{"issue":"9","key":"10.1016\/j.jbo.2024.100596_b0230","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s11999.0000000000000243","article-title":"Does denosumab change the Giant cell tumor treatment strategy? lessons Learned from Early Experience","volume":"476","author":"Agarwal","year":"2018","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"12","key":"10.1016\/j.jbo.2024.100596_b0235","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2024.100596_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2017.01.028","article-title":"Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long?","volume":"76","author":"Palmerini","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2024.100596_b0245","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820934822","article-title":"Denosumab for effective tumor size reduction in patients with Giant cell tumors of the bone: a systematic review and meta-analysis","volume":"27","author":"Yayan","year":"2020","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.jbo.2024.100596_b0250","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jos.2019.05.003","article-title":"Denosumab in giant cell tumour of bone in the pelvis and sacrum: long-term therapy or bone resection?","volume":"25","author":"Sambri","year":"2020","journal-title":"J. Orthop. Sci."},{"issue":"5","key":"10.1016\/j.jbo.2024.100596_b0255","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/CAD.0000000000000859","article-title":"A case of pelvic giant cell tumor of bone, complete remission with denosumab: long duration of response","volume":"31","author":"Bilgetekin","year":"2020","journal-title":"Anticancer Drugs"},{"issue":"18","key":"10.1016\/j.jbo.2024.100596_b0260","article-title":"Giant cell tumour of bone in os sacrum of a prepubertal girl - surgical and medical treatment with zoledronate and denosumab","volume":"19","author":"Beck-Nielsen","year":"2023","journal-title":"Bone Rep."},{"issue":"3","key":"10.1016\/j.jbo.2024.100596_b0265","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3892\/mco.2017.1137","article-title":"Successful treatment with denosumab in a patient with sacral giant cell tumor of bone refractory to combination therapy with arterial embolization and zoledronic acid: a case report","volume":"6","author":"Nishimura","year":"2017","journal-title":"Mol Clin Oncol."},{"key":"10.1016\/j.jbo.2024.100596_b0270","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1185\/030079904125004475","article-title":"Bone safety of long-term bisphosphonate treatment","volume":"20","author":"Rodan","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13569-016-0056-0","article-title":"Current status and unanswered questions on the use of denosumab in giant cell tumor of bone","volume":"6","author":"Gaston","year":"2016","journal-title":"Clin Sarcoma Res."},{"issue":"5","key":"10.1016\/j.jbo.2024.100596_b0280","doi-asserted-by":"crossref","first-page":"e248837","DOI":"10.1136\/bcr-2022-248837","article-title":"Total neurological recovery after surgical decompression and treatment with denosumab of large unresectable spinal giant cell tumour expanding to mediastinum","volume":"15","author":"Anusitviwat","year":"2022","journal-title":"BMJ Case Rep."},{"issue":"2","key":"10.1016\/j.jbo.2024.100596_b0285","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/biomedicines10020372","article-title":"A rationale for the activity of bone Target therapy and tyrosine kinase inhibitor combination in Giant cell tumor of bone and desmoplastic fibroma: translational evidences","volume":"10","author":"De Vita","year":"2022","journal-title":"Biomedicines."},{"issue":"7","key":"10.1016\/j.jbo.2024.100596_b0290","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/oncolo\/oyac066","article-title":"Giant cell tumor of bone: effect of longer dosing intervals of denosumab on tumor control and bone-related complications","volume":"27","author":"Jiang","year":"2022","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jbo.2024.100596_b0295","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/CORR.0000000000001074","article-title":"Is treatment with denosumab associated with local recurrence in patients with Giant cell tumor of bone treated with curettage? a systematic review","volume":"478","author":"Tsukamoto","year":"2020","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"12","key":"10.1016\/j.jbo.2024.100596_b0300","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1159\/000334549","article-title":"Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor","volume":"34","author":"Chaudhary","year":"2011","journal-title":"Onkologie"},{"key":"10.1016\/j.jbo.2024.100596_b0305","doi-asserted-by":"crossref","unstructured":"Gille O, Oliveira Bde A, Guerin P, Lepreux S, Richez C, Vital JM. Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy. Spine (Phila Pa 1976). 2012 Mar 15;37(6):E396-9. doi: 10.1097\/BRS.0b013e31823ed70d.","DOI":"10.1097\/BRS.0b013e31823ed70d"},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ecl.2016.09.009","article-title":"Drug-related adverse events of osteoporosis therapy","volume":"46","author":"Khan","year":"2017","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.jbo.2024.100596_b0315","doi-asserted-by":"crossref","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. doi: 10.1016\/j.joms.2014.04.031. Erratum in: J Oral Maxillofac Surg. 2015 Jul;73(7):1440. Erratum in: J Oral Maxillofac Surg. 2015 Sep;73(9):1879. PMID: 25234529.","DOI":"10.1016\/j.joms.2014.04.031"},{"issue":"12","key":"10.1016\/j.jbo.2024.100596_b0320","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100596_b0325","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"86","author":"Schilcher","year":"2015","journal-title":"Acta Orthop."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424000769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424000769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T16:00:13Z","timestamp":1713974413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137424000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":65,"alternative-id":["S2212137424000769"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100596","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100596"}}